Several randomized phase III trials comparing gefitinib or erlotinib to platinum-based chemotherapies for treatment-naïve patients with NSCLC and EGFR mutations demonstrated that these drugs significantly improve the PFS compared to that obtained with platinum-based chemotherapies [10,11,12,13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.